CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
EQS Group
Issuer: CureVac / Key word(s): Annual Results
24.04.2024 / 13:06 CET/CEST
The issuer is solely responsible for the..
Issuer: CureVac / Key word(s): Annual Results
24.04.2024 / 13:06 CET/CEST
The issuer is solely responsible for the..
Dublin, April 10, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Adjuvants Market Size, Share & Industry Trends Analysis, 2023-2030"..
· Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure..